Status:
UNKNOWN
Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
William Marsh Rice University
Conditions:
COVID-19 Infection
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study investigates a new diagnostic test in detecting SARS-CoV-2, the virus that causes the disease COVID-19. This may help to improve testing for COVID-19.
Detailed Description
PRIMARY OBJECTIVE: I. To evaluate the clinical performance of a novel point-of-care diagnostic test for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes t...
Eligibility Criteria
Inclusion
- Qualifies for SARS-CoV-2 testing at MD Anderson, Lyndon B. Johnson (LBJ) hospital, or affiliated sites (may include MD Anderson and LBJ patients and employees) according to institutional criteria at time of enrollment
- Willing and able to provide informed consent
- Ability to perform protocol-required activities
- Able to speak and read English or Spanish
Exclusion
- Patient or provider decision not to perform SARS-CoV-2 testing
Key Trial Info
Start Date :
April 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2023
Estimated Enrollment :
257 Patients enrolled
Trial Details
Trial ID
NCT04513990
Start Date
April 9 2020
End Date
April 30 2023
Last Update
December 22 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Lyndon Baines Johnson General Hospital
Houston, Texas, United States, 77026-1967
2
M D Anderson Cancer Center
Houston, Texas, United States, 77030